mTOR 抑制剂治疗晚期肾细胞癌。
mTOR inhibitors in advanced renal cell carcinoma.
机构信息
Genitourinary Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 353 East 68th Street, New York, NY 10065, USA.
出版信息
Hematol Oncol Clin North Am. 2011 Aug;25(4):835-52. doi: 10.1016/j.hoc.2011.04.008.
Abstract
Better understanding of the molecular biology of renal cell carcinoma (RCC) has led to the development of several targeted anti-cancer agents, several of which have since received approval for treatment of advanced disease. Two of these, the intravenous agent temsirolimus and the oral everolimus, exhibit antitumor effects through inhibition of the mammalian target of rapamycin (mTOR) pathway. This article reviews their mechanisms of action in the context of the current understanding of RCC pathophysiology, the clinical data leading to their approval, class-specific toxicities, potential molecular mechanisms behind treatment resistance and novel treatment approaches for RCC that incorporate mTOR blockade.
摘要
更好地理解肾细胞癌（RCC）的分子生物学导致了几种靶向抗癌药物的发展，其中几种药物已被批准用于治疗晚期疾病。其中两种，静脉注射的替西罗莫司和口服的依维莫司，通过抑制哺乳动物雷帕霉素靶蛋白（mTOR）途径发挥抗肿瘤作用。本文综述了它们在目前对 RCC 病理生理学的理解、导致其批准的临床数据、特定于类别的毒性、治疗耐药背后的潜在分子机制以及包含 mTOR 阻断的 RCC 新治疗方法的背景下的作用机制。
相似文献
1
mTOR inhibitors in advanced renal cell carcinoma.mTOR 抑制剂治疗晚期肾细胞癌。
Hematol Oncol Clin North Am. 2011 Aug;25(4):835-52. doi: 10.1016/j.hoc.2011.04.008.
2
Everolimus for the treatment of advanced renal cell carcinoma.依维莫司治疗晚期肾细胞癌。
Expert Opin Pharmacother. 2011 May;12(7):1143-55. doi: 10.1517/14656566.2011.571382. Epub 2011 Apr 7.
3
A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma.一项在晚期肾细胞癌患者中使用瓦他拉尼和依维莫司联合抑制VEGFR和mTOR的Ib期研究。
Clin Genitourin Cancer. 2014 Aug;12(4):241-50. doi: 10.1016/j.clgc.2013.11.020. Epub 2013 Nov 14.
4
Sunitinib, sorafenib and mTOR inhibitors in renal cancer.舒尼替尼、索拉非尼及mTOR抑制剂在肾癌中的应用
J BUON. 2007 Sep;12 Suppl 1:S151-62.
5
Rechallenge with mTOR inhibitors in metastatic renal cell carcinoma patients who progressed on previous mTOR inhibitor therapy.先前接受过 mTOR 抑制剂治疗后进展的转移性肾细胞癌患者中，用 mTOR 抑制剂进行再挑战。
Oncology. 2013;85(1):8-13. doi: 10.1159/000350005. Epub 2013 Jun 21.
6
First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database Consortium.转移性肾细胞癌中雷帕霉素的一线哺乳动物靶点抑制：来自国际转移性肾细胞癌数据库联盟的实践模式分析。
Clin Genitourin Cancer. 2014 Oct;12(5):335-40. doi: 10.1016/j.clgc.2014.03.003. Epub 2014 Mar 15.
7
Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: pharmacokinetic considerations and clinical implications.口服和静脉注射的 mTOR 抑制剂治疗转移性肾细胞癌：药代动力学考虑和临床意义。
Cancer Treat Rev. 2013 Nov;39(7):784-92. doi: 10.1016/j.ctrv.2012.12.012. Epub 2013 Jan 30.
8
mTOR pathway inhibition in renal cell carcinoma.mTOR 通路抑制在肾细胞癌中的作用。
Urol Oncol. 2012 Jul-Aug;30(4):356-61. doi: 10.1016/j.urolonc.2009.11.008. Epub 2010 Mar 5.
9
Everolimus in renal cell carcinoma.依维莫司用于肾细胞癌治疗
Drugs Today (Barc). 2010 Aug;46(8):557-66. doi: 10.1358/dot.2010.46.8.1516824.
10
Differentiating mTOR inhibitors in renal cell carcinoma.鉴别肾细胞癌中的 mTOR 抑制剂。
Cancer Treat Rev. 2013 Nov;39(7):709-19. doi: 10.1016/j.ctrv.2012.12.015. Epub 2013 Feb 21.
引用本文的文献
1
Second-Line Systemic Therapies in Metastatic Renal Cell Carcinoma: Current Insights and Future Directions.转移性肾细胞癌的二线全身治疗：当前见解与未来方向
J Cancer Immunol (Wilmington). 2025;7(2):81-94. doi: 10.33696/cancerimmunol.7.107.
2
Decoding tumor angiogenesis: pathways, mechanisms, and future directions in anti-cancer strategies.解码肿瘤血管生成：抗癌策略中的途径、机制及未来方向
Biomark Res. 2025 Apr 18;13(1):62. doi: 10.1186/s40364-025-00779-x.
3
Prdx5 in the Regulation of Tuberous Sclerosis Complex Mutation-Induced Signaling Mechanisms.PRDX5 在结节性硬化症突变诱导的信号机制中的调节作用。
Cells. 2023 Jun 24;12(13):1713. doi: 10.3390/cells12131713.
4
Cellular and Molecular Players in the Tumor Microenvironment of Renal Cell Carcinoma.肾细胞癌肿瘤微环境中的细胞与分子参与者
J Clin Med. 2023 Jun 7;12(12):3888. doi: 10.3390/jcm12123888.
5
Characterization of Tumor and Immune Tumor Microenvironment of Primary Tumors and Metastatic Sites in Advanced Renal Cell Carcinoma Patients Based on Response to Nivolumab Immunotherapy: Preliminary Results from the Meet-URO 18 Study.基于纳武利尤单抗免疫治疗反应的晚期肾细胞癌患者原发性肿瘤和转移部位的肿瘤及免疫肿瘤微环境特征：Meet-URO 18研究的初步结果
Cancers (Basel). 2023 Apr 21;15(8):2394. doi: 10.3390/cancers15082394.
6
Protein posttranslational modifications in health and diseases: Functions, regulatory mechanisms, and therapeutic implications.健康与疾病中的蛋白质翻译后修饰：功能、调控机制及治疗意义
MedComm (2020). 2023 May 2;4(3):e261. doi: 10.1002/mco2.261. eCollection 2023 Jun.
7
Dual mTORC1/2 Inhibition Synergistically Enhances AML Cell Death in Combination with the BCL2 Antagonist Venetoclax.双重 mTORC1/2 抑制与 BCL2 拮抗剂 Venetoclax 联合协同增强 AML 细胞死亡。
Clin Cancer Res. 2023 Apr 3;29(7):1332-1343. doi: 10.1158/1078-0432.CCR-22-2729.
8
Adjuvant therapy options in renal cell carcinoma - targeting the metastatic cascade.肾细胞癌的辅助治疗选择 - 靶向转移级联。
Nat Rev Urol. 2023 Mar;20(3):179-193. doi: 10.1038/s41585-022-00666-2. Epub 2022 Nov 11.
9
IL-8 and its role as a potential biomarker of resistance to anti-angiogenic agents and immune checkpoint inhibitors in metastatic renal cell carcinoma.白细胞介素-8及其作为转移性肾细胞癌中抗血管生成药物和免疫检查点抑制剂耐药潜在生物标志物的作用。
Front Oncol. 2022 Aug 19;12:990568. doi: 10.3389/fonc.2022.990568. eCollection 2022.
10
Glutaminase inhibition in renal cell carcinoma therapy.肾细胞癌治疗中的谷氨酰胺酶抑制作用
Cancer Drug Resist. 2019 Jun 19;2(2):356-364. doi: 10.20517/cdr.2018.004. eCollection 2019.
本文引用的文献
1
Everolimus- and temsirolimus-associated enteritis: report of three cases.
J Clin Oncol. 2011 May 10;29(14):e404-6. doi: 10.1200/JCO.2010.33.5984. Epub 2011 Feb 28.
2
The mammalian target of rapamycin pathway is widely activated without PTEN deletion in renal cell carcinoma metastases.哺乳动物雷帕霉素靶蛋白通路在肾细胞癌转移中广泛激活，而并非由于 PTEN 缺失。
Cancer. 2011 Jan 15;117(2):290-300. doi: 10.1002/cncr.25402. Epub 2010 Sep 9.
3
Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus.人类癌细胞中 PI3K 和 KRAS 信号通路的失调决定了它们对依维莫司的反应。
J Clin Invest. 2010 Aug;120(8):2858-66. doi: 10.1172/JCI37539. Epub 2010 Jul 26.
4
Temsirolimus in VEGF-refractory metastatic renal cell carcinoma.特西罗莫司治疗血管内皮生长因子耐药的转移性肾细胞癌。
Ann Oncol. 2011 Jan;22(1):145-148. doi: 10.1093/annonc/mdq320. Epub 2010 Jul 1.
5
New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.哺乳动物雷帕霉素靶蛋白信号通路抑制剂在癌症治疗中的应用
Expert Opin Investig Drugs. 2010 Aug;19(8):919-30. doi: 10.1517/13543784.2010.499121.
6
Targeting mTOR in cancer: renal cell is just a beginning.靶向 mTOR 治疗癌症：肾细胞肿瘤只是一个开始。
Target Oncol. 2010 Dec;5(4):269-80. doi: 10.1007/s11523-010-0141-x. Epub 2010 Jun 20.
7
Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors.依维莫司治疗转移性肾细胞癌的 3 期临床试验：最终结果和预后因素分析。
Cancer. 2010 Sep 15;116(18):4256-65. doi: 10.1002/cncr.25219.
8
Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma.晚期肾细胞癌患者使用 mTOR 抑制剂相关的紧急毒性。
Anticancer Drugs. 2010 Jun;21(5):478-86. doi: 10.1097/cad.0b013e32833760bf.
9
Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma.贝伐珠单抗联合依维莫司治疗晚期肾细胞癌的 II 期临床试验。
J Clin Oncol. 2010 May 1;28(13):2131-6. doi: 10.1200/JCO.2009.26.3152. Epub 2010 Apr 5.
10
Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma.晚期肾细胞癌依维莫司治疗后的非传染性肺炎。
Am J Respir Crit Care Med. 2010 Aug 1;182(3):396-403. doi: 10.1164/rccm.200911-1720OC. Epub 2010 Mar 1.
Zotero 插件